OncoMatch/Clinical Trials/NCT06102863
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Is NCT06102863 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day); for atypical endometrial hyperplasia and endometrial carcinoma stage i.
Treatment: statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day); — To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Statins in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Disease stage
Required: Stage IA
Demographics
Prior therapy
Cannot have received: nursery therapy drugs (progesterone, GNRH-a) (progesterone, GNRH-a)
Exception: newly treated patients only
Newly treated patients: did not use any nursery therapy drugs (progesterone, GNRH-a)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06102863 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior nursery therapy drugs (progesterone, GNRH-a) disqualifies patients from enrollment.
What disease stage is eligible?
Stage IA is required.
Is there an age limit?
Yes. Patients must be 45 years or younger and at least 17 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages